TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/03/2025
Voltar para busca
Dado oficial do USPTO
MORPHOSYS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
MORPHOSYS
ST13
US500000097042228Classe
1, 5, 42
Pedido
97042228
Registro
7071326
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
26/03/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
23/09/2021
Data de registro
06/06/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/06/2023
Última transação
26/03/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
4
Tipo de titular
99
Localização do titular
Planegg, DE
Examinador
WANG, YUAN YUAN
Unidade examinadora
L90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
MorphoSys AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
reagents for scientific and medical research for use in the research and production of small molecule pharmaceuticals; active pharmaceutical ingredientsantibodiesproteins and small molecules for use in the manufacture of pharmaceuticalsbiopharmaceuticalsvaccinesfinished drug products; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines
Classe 5
pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules for the treatment and prevention of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; small molecule compounds for use as drug delivery agents in pharmaceuticals; small molecule compounds being pharmaceuticals for the treatment and prevention of diseases and disordersmetabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis in humans; small molecule pharmaceuticals for the treatment of diseases and conditionsmetabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; Pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disordersmetabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; antibodies sold as a component ingredient of pharmaceuticals for the treatment of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis for the treatment of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; Clinical medical reagents; Biological preparations for medical purposesfor the treatment of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; pharmaceutical and veterinary preparationsagents and substances for the treatment of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis
Classe 42
Pharmaceutical research and development of pharmaceutical preparationsmedicines and vaccines; providing medical and scientific research information; Scientific research in the nature of conducting clinical trials for others; scientific and technological servicesscientific researchanalysistesting services in the fields of analytical chemistrybiochemistrymedicinal chemistrydrug developmentbiotechnologymicrobiology and molecular biology; research and design servicesresearch and development in the field of antibodies and clinical research in connection with the treatment and prevention of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
21/03/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/03/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/03/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/03/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/03/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/06/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
06/06/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/03/2023
PUBO
PUBLISHED FOR OPPOSITION
21/03/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/02/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
10/02/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/02/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
10/02/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/02/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
01/02/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/02/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
01/02/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/01/2023
ALIE
ASSIGNED TO LIE
09/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/11/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/06/2022
GNRT
NON-FINAL ACTION E-MAILED
27/06/2022
CNRT
NON-FINAL ACTION WRITTEN
27/06/2022
DOCK
ASSIGNED TO EXAMINER
24/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/10/2021
NWAP
NEW APPLICATION ENTERED
27/09/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MORPHOSYS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.